Cromakalim
Alternative Names: BRL 34915; ChromakalimLatest Information Update: 02 Jul 2023
At a glance
- Originator GlaxoSmithKline
- Developer GSK
- Class Antiallergics; Antiarrhythmics; Antiasthmatics; Antihypertensives; Benzopyrans; Pyrroles; Small molecules
- Mechanism of Action KATP channel stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Arrhythmias; Asthma; Cardiomyopathies; Hypertension; Ischaemic heart disorders; Peptic ulcer
Most Recent Events
- 16 Dec 1999 Discontinued-Preclinical for Cardiomyopathy in Canada (Unknown route)
- 16 Dec 1999 Discontinued-Preclinical for Peptic ulcer in India (Unknown route)
- 28 Sep 1998 No-Development-Reported for Cardiomyopathy in Canada (Unknown route)